Akaal Pharma, Australia extends collaboration with GVK BIO

GVK BIO’s Formulation Development business unit in Bengaluru has developed robust and scalable process for novel topical AKP-11 ointment. 

 

GVK BIO plans to support clinical studies of Akaal Pharma’s topical psoriasis drug by providing clinical supplies, manufacturing and  analytical support. Discussions are also on-going to work towards exploring appropriate commercialization packaging and various formulations for the topical use in other inflammatory diseases.

 

Seetharaju Gembali, Senior Vice President, Formulation R&D of GVK BIO, said: “Strengthening of our partnership with Akaal Pharma is testimonial to our expertise in the Formulation Development and we look forward to working with other clients.”

 

Dr. Dale Dhanoa, CEO of Akaal Pharma, said: “We have had a very efficient CRO relationshipwith GVK for our clinical trials supplies support due to GVK BIO’s experience, capabilities and facilities. We areexcited to advance our First-in-Class multimodal acting topicaldrug candidate AKP-11 into Phase 2 stage of clinical developmentfor the treatment of psoriasis. There are several other inflammatory diseases that we are targeting with our clinical compound and are currently exploring various formulations for its topical applications.”